Analysts/Institutional Investor Meet/Con. Call Updates

November 02, 2026 BSE Limited National Stock Exchange of India Limited Floor 25, P.J. Tower Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended – Transcript of the Investors’ Conference Call for the quarter and half year ended September 30, 2026 Dear Sir/Madam, Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we enclose the transcript of Investors’ Conference Call for un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, held on October 27, 2026. The above details will also be available on the website of the Company at: https://jubilantingrevia.com/investors/financials/quarterly-results We request you to take the same on record. Thanking you, Yours faithfully, For Jubilant Ingrevia Limited Deepanjali Gulati Company Secretary & Compliance Officer Encl.: as above List of management attendees 1. Mr. Shyam Bhartia, Chairman 2. Mr. Hari Bhartia, Co-Chairman 3. Mr. Deepak Jain, CEO and Managing Director 4. Mr. Varun Gupta, CFO – Jubilant Ingrevia Limited 5. Mr. Pavleen Taneja, Head – Investor Relations External participants during Q&A session 1. Siddharth Gadekar, Equirus 2. Abhijit Akella, Kotak Institutional Equities 3. Nitesh Dhoot, Anand Rathi Institutional Equities 4. Ravi Mehta, OneUp Financial 5. Ruchit Agrawal, Union Mutual Fund 6. Harsh Shah, Individual Investor Page 1 of 12 Jubilant Ingrevia Limited Q2 & H1 FY27 Earnings Conference Call Transcript October 27, 2026 Moderator: Ladies and gentlemen, good day and welcome to Jubilant Ingrevia's Q2 and H1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Pavleen Taneja, Head of Investor Relations at Jubilant Ingrevia Limited. Thank you and over to you, sir. Pavleen Taneja: Thank you, Iqra. Good evening, everyone. Thank you for joining the Q2 FY2027 Earnings Conference Call of Jubilant Ingrevia Limited. I would like to remind you that some of some of the statements made on the call today could be forward-looking in nature and a detailed disclaimer in this regard has been included in the press release and the result presentation that has been shared on our website. On the call today, we have Mr. Shyam Bhartia, Chairman, Mr. Hari Bhartia, Co-Chairman, Mr. Deepak Jain, CEO and Managing Director and Mr. Varun Gupta, CFO, Jubilant Ingrevia Limited. I now invite Mr. Shyam Bhartia to share his comments. Shyam Bhartia: Thank you, Pavleen. Very good evening to all of you. We are pleased to report that we continued to sustain strong growth momentum in Q2 with revenue growing 24% year-on-year and EBITDA increasing 51%, reflecting disciplined execution across our businesses. Our quarterly EBITDA has more than doubled over the past 3 years, underscoring the successful execution of our pinnacle strategy and continued focus on disciplined cost management. This momentum was also reflected in our strong first half performance with revenue growing 25% and EBITDA by 44% year-on-year. We are also delighted to announce that we have signed an agreement to acquire 40% stake in Zettaone Technologies Limited. This marks our entry into electronics design management system space which will enable us to offer more integrated value proposition to customers in the electronics and semiconductor sectors. Now let me take you through the key developments across the market we operate in. Acetyls Amid continued geopolitical uncertainties, volumes remain stable while pharma crude prices supported improved realization. However, input and utility costs during the quarter partially offset the benefits of improved pricing. Pharmaceuticals Page 2 of 12 The pharmaceutical segment continues to grow supported by steady volumes and sustained demand for intermediates. Agro-chemicals The agro-chemical segment remained under pressure with stable volumes but muted pricing, primarily due to excess capacity in China. Personal care We continued to witness strong volume growth in personal care alongside increasing traction with new customers seeking outsourcing partnerships. Nutrition The nutrition segment maintained steady volumes despite some softening in vitamin B3 pricing in the animal feed segment over the past few weeks. Semiconductors and electronics. We continue to see strong growth in our new molecule pipeline with encouraging customer traction, particularly in Japan. This reinforces our confidence in the growth opportunities emerging in these sectors. Now let me share few details of our future outlook. Our pinnacle journey continues to progress well, supported by strong revenue and EBITDA growth, along with robust pipeline of growth opportunities. We remain confident of sustaining this momentum with growth expected across all three business segments in FY2027. Within Acetyls in particular, we anticipate higher volumes supported by planned closures in Europe. Additionally, our new multipurpose plant remains on track for commissioning by the year-end. This will further strengthen our CDMO and fine chemicals growth roadmap and enhance our ability to capitalize on emerging opportunities. With this, I hand over to Deepak for detailed business overview. Deepak Jain: Thank you very much, Mr. Bhartia, and a very good evening to all of you. We appreciate your participation in our Q2 and H1 FY27 investor call. Let me start by giving a quick overview of our business. We continued to execute well against our strategic priorities despite ongoing global uncertainties. Our diversified sourcing capabilities, strong customer partnerships, and agile operations enabled us to effectively navigate these disruptions and price volatility while managing cost pass-throughs. This execution strength is clearly reflected in our performance during Q2 and H1 FY27. We delivered another strong quarter in Q2, reinforcing our performance for H1 FY27. Revenue reached an all-time high of INR1,394 crore, up 24% year-on-year, supported by stronger realizations and stable volumes. EBITDA rose 51% year-on- year to INR 221 crore, the highest in the last three years, while PAT increased 60% year-on-year to INR111 crore. In specialty chemicals, the business delivered a strong performance with revenue reaching INR560 crore, up 16% year-on-year and 5% sequentially, led by healthy volume growth across fine chemicals and CDMO. We delivered EBITDA of INR140 crore, translating into a strong EBITDA margin of 25%, driven by improved pricing across our value-added fine chemicals and CDMO portfolio. In pyridine and picolines, volumes remained stable despite continued Page 3 of 12 softness in pricing. Our ongoing cost optimization and capacity debottlenecking initiatives are expected to strengthen performance going forward. Our fine chemicals business delivered broad-based growth across pyridine and diketene derivatives, supported by improved pricing with particularly strong momentum in the diketene portfolio. In personal care, we have multiple products under development and are seeing increasing traction across key personal care segments and customers. Our CDMO business continued to build strong momentum across agro, pharma, personal care, and semiconductors. Agro delivered healthy volume growth led by higher innovator CDMO volumes, while we are seeing strong customer engagement in pharma with our US and Europe roadshows with innovators. In semiconductor [Showing first 8,000 characters — download PDF for full document]